Putting Data into Practice: A Review of Phase III and Long-Term Efficacy Data for Bimekizumab for Plaque Psoriasis.
作者信息
Beer Jacob, Hermak Sarah, Noor Omar
机构信息
Dr. Beer and Ms. Hermak are with the Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery at the University of Miami in Miami, Florida.
Dr. Noor is a board-certified dermatologist practicing in New York and New Jersey and is the co-owner of Rao Dermatology.
出版信息
J Clin Aesthet Dermatol. 2024 May;17(5 Suppl 2):S7-S10.
Abstract
摘要
相似文献
1
Putting Data into Practice: A Review of Phase III and Long-Term Efficacy Data for Bimekizumab for Plaque Psoriasis.将数据应用于实践：优时比单抗治疗斑块状银屑病的III期及长期疗效数据综述
J Clin Aesthet Dermatol. 2024 May;17(5 Suppl 2):S7-S10.
2
Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge.用于治疗银屑病的比美吉珠单抗：当前知识综述
Psoriasis (Auckl). 2022 Jun 8;12:127-137. doi: 10.2147/PTT.S367744. eCollection 2022.
3
Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials.比美克珠单抗治疗中重度斑块状银屑病患者的安全性：来自 2 期和 3 期随机临床试验的汇总结果。
JAMA Dermatol. 2022 Jul 1;158(7):735-744. doi: 10.1001/jamadermatol.2022.1185.
4
Bimekizumab in the Treatment of Plaque Psoriasis: Focus on Patient Selection and Perspectives.比美吉珠单抗治疗斑块状银屑病：聚焦患者选择与展望
Patient Prefer Adherence. 2023 Jun 30;17:1541-1549. doi: 10.2147/PPA.S350760. eCollection 2023.
5
Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation.中度至重度斑块状银屑病患者的比美吉珠单抗治疗：药物安全性评估
Expert Opin Drug Saf. 2023 Jan-Jun;22(5):355-362. doi: 10.1080/14740338.2023.2218086. Epub 2023 Jun 19.
6
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.比美吉珠单抗治疗中重度斑块型银屑病的疗效和安全性（BE READY）：一项多中心、双盲、安慰剂对照、随机撤药阶段 3 期临床试验。
Lancet. 2021 Feb 6;397(10273):475-486. doi: 10.1016/S0140-6736(21)00126-4.
7
Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study.比美吉珠单抗治疗中度至重度斑块型银屑病：来自一项 IIa 期、随机、双盲、多中心研究的疗效、安全性、药代动力学、药效学和转录组学。
Br J Dermatol. 2022 Apr;186(4):652-663. doi: 10.1111/bjd.20827. Epub 2021 Dec 27.
8
Review of bimekizumab in the treatment of psoriasis.中文标题：比美吉单抗治疗银屑病的研究进展。
Hum Vaccin Immunother. 2022 Nov 30;18(6):2119767. doi: 10.1080/21645515.2022.2119767. Epub 2022 Sep 12.
9
Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial.在中重度斑块型银屑病患者中，经过 2 年的比美吉珠单抗治疗的安全性和有效性：来自 BE SURE 随机对照试验和 BE BRIGHT 试验开放标签扩展的长期结果。
Br J Dermatol. 2023 Jan 23;188(1):22-31. doi: 10.1093/bjd/ljac021.
10
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.比美吉珠单抗与乌司奴单抗治疗中度至重度斑块型银屑病（BE VIVID）：一项为期 52 周、多中心、双盲、活性对照和安慰剂对照的 3 期临床试验的疗效和安全性。
Lancet. 2021 Feb 6;397(10273):487-498. doi: 10.1016/S0140-6736(21)00125-2.
本文引用的文献
1
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials.布罗达单抗治疗中重度斑块状银屑病的安全性：来自随机III期试验长达3年治疗的汇总数据
Br J Dermatol. 2024 Mar 15;190(4):477-485. doi: 10.1093/bjd/ljad429.
2
Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial.在中重度斑块型银屑病患者中，比美吉珠单抗维持治疗应答 3 年：来自 BE BRIGHT 开放性扩展试验的结果。
Br J Dermatol. 2023 May 24;188(6):749-759. doi: 10.1093/bjd/ljad035.
3
Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials.在从阿达木单抗、乌司奴单抗或司库奇尤单抗转换治疗的中重度斑块型银屑病患者中，比美吉珠单抗的疗效和安全性：III 期/IIIb 期试验结果。
Br J Dermatol. 2023 Feb 22;188(3):330-340. doi: 10.1093/bjd/ljac089.
4
Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis.比美吉珠单抗及其他生物制剂治疗中度至重度斑块状银屑病的疗效：系统文献综述与网状Meta分析
Dermatol Ther (Heidelb). 2022 Aug;12(8):1777-1792. doi: 10.1007/s13555-022-00760-8. Epub 2022 Jul 7.
5
Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials.比美克珠单抗治疗中重度斑块状银屑病患者的安全性：来自 2 期和 3 期随机临床试验的汇总结果。
JAMA Dermatol. 2022 Jul 1;158(7):735-744. doi: 10.1001/jamadermatol.2022.1185.
6
Risk of candidiasis associated with interleukin-17 inhibitors: A real-world observational study of multiple independent sources.与白细胞介素-17抑制剂相关的念珠菌病风险：一项来自多个独立来源的真实世界观察性研究。
Lancet Reg Health Eur. 2021 Nov 22;13:100266. doi: 10.1016/j.lanepe.2021.100266. eCollection 2022 Feb.
7
Bimekizumab versus Secukinumab in Plaque Psoriasis.比美吉珠单抗与司库奇尤单抗治疗斑块状银屑病的疗效比较。
N Engl J Med. 2021 Jul 8;385(2):142-152. doi: 10.1056/NEJMoa2102383. Epub 2021 Apr 23.
8
Bimekizumab versus Adalimumab in Plaque Psoriasis.比美吉单抗与阿达木单抗治疗斑块状银屑病的疗效比较。
N Engl J Med. 2021 Jul 8;385(2):130-141. doi: 10.1056/NEJMoa2102388. Epub 2021 Apr 23.
9
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.比美吉珠单抗与乌司奴单抗治疗中度至重度斑块型银屑病（BE VIVID）：一项为期 52 周、多中心、双盲、活性对照和安慰剂对照的 3 期临床试验的疗效和安全性。
Lancet. 2021 Feb 6;397(10273):487-498. doi: 10.1016/S0140-6736(21)00125-2.
10
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.比美吉珠单抗治疗中重度斑块型银屑病的疗效和安全性（BE READY）：一项多中心、双盲、安慰剂对照、随机撤药阶段 3 期临床试验。
Lancet. 2021 Feb 6;397(10273):475-486. doi: 10.1016/S0140-6736(21)00126-4.
Zotero 插件